RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

NCT00358215 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2278

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure
Anemia
Cardiovascular Disease
Ventricular Dysfunction
Congestive Heart Failure

Interventions

DRUG: Darbepoetin alfa
DRUG: Placebo

Sponsor

Amgen